Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 third quarter ended March 31, 2023 and provided

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23:
Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23


Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23

STAAR Surgical to Report First Quarter Results on May 3, 2023: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report First Quarter Results on May 3, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has renewed its

Dexcom Reports First Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports First Quarter 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.



First Quarter 2023 Financial Highlights:




  • Revenue grew 18% versus the same

Chemed To Report First-Quarter 2023 Earnings April 26, Related Conference Call To Be Held On April 27:
Chemed To Report First-Quarter 2023 Earnings April 26, Related Conference Call To Be Held On April 27


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2023, on Wednesday, April 26, 2023, following the close of trading on the

Acadia Healthcare Reports First Quarter 2023 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports First Quarter 2023 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2023.



First Quarter Highlights




  • Revenue totaled $704.3 million, an

Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes


DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes

Chemed Reports First-Quarter 2023 Results:
Chemed Reports First-Quarter 2023 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech